


Penicillin V Potassium

Cat. No.:	HY-B0975
CAS No.:	132-98-9
Molecular Formula:	C ₁₆ H ₁₇ KN ₂ O ₅ S
Molecular Weight:	388.48
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 12 mg/mL (30.89 mM; Need ultrasonic)
H₂O : 6 mg/mL (15.44 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.5741 mL	12.8707 mL	25.7414 mL
	5 mM	0.5148 mL	2.5741 mL	5.1483 mL
	10 mM	0.2574 mL	1.2871 mL	2.5741 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 100 mg/mL (257.41 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 1.2 mg/mL (3.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.2 mg/mL (3.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.2 mg/mL (3.09 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, *C. difficile* and *S. aureus*. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis^{[1][2][3][4]}.

IC₅₀ & Target

β-lactam

In Vitro	<p>Penicillin V (0.002-8.0 mg/L) inhibits the growth of Streptococci, with the minimum inhibitory concentrations (MICs) of 0.004-0.008 mg/L^[2].</p> <p>Penicillin V (0.002-8.0 mg/L) inhibits the growth of <i>C. difficile</i>, with a MIC₉₀ of 8 mg/L^[3].</p> <p>Penicillin V (0.004-0.063 mg/L; 18 h) inhibits the growth of <i>Staphylococcus aureus</i>, with a MIC of 0.016 mg/L^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Penicillin V (0.063-0.25 mg/kg; a single s.c.) inhibits the outgrowth of <i>S. aureus</i> in mice thigh muscle^[4].</p> <p>Penicillin V (100 mg/kg; p.o. once daily for 5 d) avoids the fulminant infection of acute purulent otitis media (AOM) in rats^[5].</p> <p>Penicillin V (2 mg/kg; a single s.c.) exhibits the plasma half-life (61 min) and mean AUC (0.47 mg/L•h)^[4]^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="345 485 1515 758"> <tr> <td data-bbox="345 485 618 548">Animal Model:</td> <td data-bbox="618 485 1515 548">Specific pathogen free (SPF) male Swiss mice (20-25 g) are inoculated <i>S. aureus</i>^[4]</td> </tr> <tr> <td data-bbox="345 548 618 611">Dosage:</td> <td data-bbox="618 548 1515 611">0.063, 0.13, 0.25 mg/kg</td> </tr> <tr> <td data-bbox="345 611 618 674">Administration:</td> <td data-bbox="618 611 1515 674">A single s.c.</td> </tr> <tr> <td data-bbox="345 674 618 758">Result:</td> <td data-bbox="618 674 1515 758">Decreased the number of CFU (1.34×10⁷ counts/mL) compared to controls (3.5×10⁷ counts/mL) at the dose of 0.25 mg/kg.</td> </tr> </table>	Animal Model:	Specific pathogen free (SPF) male Swiss mice (20-25 g) are inoculated <i>S. aureus</i> ^[4]	Dosage:	0.063, 0.13, 0.25 mg/kg	Administration:	A single s.c.	Result:	Decreased the number of CFU (1.34×10 ⁷ counts/mL) compared to controls (3.5×10 ⁷ counts/mL) at the dose of 0.25 mg/kg.
Animal Model:	Specific pathogen free (SPF) male Swiss mice (20-25 g) are inoculated <i>S. aureus</i> ^[4]								
Dosage:	0.063, 0.13, 0.25 mg/kg								
Administration:	A single s.c.								
Result:	Decreased the number of CFU (1.34×10 ⁷ counts/mL) compared to controls (3.5×10 ⁷ counts/mL) at the dose of 0.25 mg/kg.								

REFERENCES

- [1]. Sabath LD, et, al. Phenoxyethylpenicillin (penicillin V) and phenethicillin. *Med Clin North Am.* 1970 Sep;54(5):1101-11.
- [2]. Kamme C, et, al. In vitro effect on group A streptococci of loracarbef versus cefadroxil, cefaclor and penicillin V. *Scand J Infect Dis.* 1993;25(1):37-42.
- [3]. Norén T, et, al. In vitro susceptibility to 17 antimicrobials of clinical *Clostridium difficile* isolates collected in 1993-2007 in Sweden. *Clin Microbiol Infect.* 2010 Aug;16(8):1104-10.
- [4]. Overbosch D, et, al. Comparative pharmacodynamics and clinical pharmacokinetics of phenoxyethylpenicillin and pheneticillin. *Br J Clin Pharmacol.* 1985 May;19(5):657-68.
- [5]. Hermansson A, et, al. Prevention of experimental acute otitis media with penicillin V. *Acta Otolaryngol.* Jan-Feb 1990;109(1-2):119-23.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA